Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Edgewise Therapeutics Inc (EWTX)

Edgewise Therapeutics Inc (EWTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire - Wed Apr 1, 7:00AM CDT

BOULDER, Colo. , April 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics...

EWTX : 33.16 (+0.06%)
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up PR Newswire - Tue Mar 10, 6:00AM CDT

–The MESA data show stabilization of function in participants on sevasemten versus the predicted functional decline observed in Becker natural history studies –

EWTX : 33.16 (+0.06%)
Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026 PR Newswire - Wed Mar 4, 7:00AM CST

BOULDER, Colo. , March 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present...

EWTX : 33.16 (+0.06%)
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference PR Newswire - Tue Mar 3, 7:00AM CST

BOULDER, Colo. , March 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 2026 Muscular...

EWTX : 33.16 (+0.06%)
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire - Mon Mar 2, 8:30AM CST

BOULDER, Colo. , March 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics...

EWTX : 33.16 (+0.06%)
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs PR Newswire - Thu Feb 26, 7:00AM CST

–  CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026  –

EWTX : 33.16 (+0.06%)
Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 PR Newswire - Thu Feb 5, 7:00AM CST

BOULDER, Colo. , Feb. 5, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Behrad Derakhshan, Ph.D., Chief...

EWTX : 33.16 (+0.06%)
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire - Mon Feb 2, 7:00AM CST

BOULDER, Colo. , Feb. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics...

EWTX : 33.16 (+0.06%)
Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026 PR Newswire - Tue Jan 13, 7:00AM CST

- Advancing robust clinical pipeline of novel therapeutics for muscular dystrophies and serious cardiac conditions -

EWTX : 33.16 (+0.06%)
Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 PR Newswire - Tue Jan 6, 7:00AM CST

BOULDER, Colo. , Jan. 6, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Kevin Koch, Ph.D., President and...

EWTX : 33.16 (+0.06%)

Barchart Exclusives

The Market Is Split on Palantir Stock. Should You Buy or Avoid Now? Barchart - 17 minutes ago
PLTR stock now faces the real test if growth can justify the valuation. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.